Particle Sciences, a Lubrizol LifeSciences company, is opening a new commercial drug product manufacturing facility at the end of 4Q18 at its existing site in Bethlehem, PA. The $60 million investment is part of an overall business unit expansion that’s expected to increase employment by 30 percent with jobs ranging from production and quality control positions to support functions such as analytical services.
 
The 5,000 sq.-ft. facility will leverage Particle Sciences’ complex formulations services and drug product manufacturing, allowing the company to offer customers a range of services from development through to commercial scale manufacturing.
 
The facility will accommodate both sterile and non-sterile finished drug products, such as ophthalmics, drug-device combination products, injectables, micro- and nanoparticulate formulations and lyophilized drugs.
 
The new space was purpose-built for more complex drug products and features state-of-the-art utilities to accommodate the production of Water for Injection (WFI) and clean steam for clean-in-place processes. 
 
Dr. Robert Lee, newly-appointed president at Particle Sciences, said “Our new facility will extend our manufacturing capabilities to phase III clinical trial materials and commercial product manufacturing. Present and future clients will benefit from the wide variety of dosage forms that the facility can handle as well as our ability to accommodate the smaller commercial batch volumes that other CMOs will not take on.”